{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01958775: Phase 3 Interventional Completed Dyslipidemia
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01472887: Phase 2 Interventional Completed Diffuse Large B-cell Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01609140: Phase 2 Interventional Completed Coronary Heart Disease
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegbovigrastim [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:eltrekibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01183897: Phase 2 Interventional Completed Neuroblastoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:hemoglobin crosfumaril (bovine) [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Tosactide is a synthetic peptide, a structural corticotropin analog (the first 28 amino acids of human adrenocorticotropin). The time course shows that the duration of action is short with a maximum effect at about 30 minutes and returns to a resting value soon after three hours. Tosactide has been used clinically.
Status:
Investigational
Source:
INN:oreptacog alfa (activated) [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02921789: Phase 2 Interventional Completed Kidney Transplantation
(2017)
Source URL:
Class:
PROTEIN
